Literature DB >> 32991241

Subcutaneous vaccine administration - an outmoded practice.

Ian F Cook1.   

Abstract

Subcutaneous vaccine (SC) administration is an outmoded practice which complicates vaccine administration recommendations. Local adverse events following immunization (AEFIs) are a recognized determinant of vaccine hesitancy/refusal which can lead to an increased prevalence of vaccine-preventable disease.This extensive narrative review provides high-grade evidence that intramuscular (IM) administration of all vaccine types [adjuvanted, live virus and non-adjuvanted (inactivated whole cell, split cell and subunit)] significantly reduces the likelihood of local adverse events. This, combined with moderate grade evidence that IM injection generates significantly greater immune response compared with SC injection, allows a strong recommendation to be made for the IM injection of all vaccines except BCG and Rotavirus.This will simplify vaccination practice, minimize the inadvertent misadministration of vaccines and potentially improve public trust in vaccination.

Entities:  

Keywords:  Literature review; immunogenicity; intramuscular; local reactogenicity; outmoded practice; subcutaneous; vaccine administration

Mesh:

Substances:

Year:  2020        PMID: 32991241      PMCID: PMC8086591          DOI: 10.1080/21645515.2020.1814094

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  74 in total

1.  Significance of cysts following injections of antigens.

Authors:  V K VOLK; F H TOP; W E BUNNEY
Journal:  Am J Public Health Nations Health       Date:  1954-10

2.  P. T. A. P.; the present position.

Authors:  L B HOLT; G BOUSFIELD
Journal:  Br Med J       Date:  1949-04-23

3.  Safety and effectiveness of multiple antigen preparations in a group of free-living children.

Authors:  V K VOLK
Journal:  Am J Public Health Nations Health       Date:  1949-10

4.  Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

Authors:  David I Bernstein; Elizabeth A Reap; Kevin Katen; Aubrey Watson; Kaitlin Smith; Pamela Norberg; Robert A Olmsted; Amy Hoeper; John Morris; Sarah Negri; Maureen F Maughan; Jeffrey D Chulay
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

5.  Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines.

Authors:  Elisabet Bergfors; Cecilia Björkelund; Birger Trollfors
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

6.  Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine.

Authors:  R M Carlsson; B A Claesson; H Käyhty; U Selstam; S Iwarson
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

7.  Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Authors:  Sharon E Frey; Frances K Newman; Jeffrey S Kennedy; Vera Sobek; Francis A Ennis; Heather Hill; Lihan K Yan; Paul Chaplin; Jens Vollmar; Bernard R Chaitman; Robert B Belshe
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

8.  Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.

Authors:  Jennifer G Wright; Brian D Plikaytis; Charles E Rose; Scott D Parker; Janiine Babcock; Wendy Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Vera A Semenova; Han Li; Jarad Schiffer; Hanan Dababneh; Sandra K Martin; Stacey W Martin; Nina Marano; Nancy E Messonnier; Conrad P Quinn
Journal:  Vaccine       Date:  2013-12-25       Impact factor: 4.169

9.  Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial.

Authors:  Josep Casajuana; Begoña Iglesias; Mireia Fàbregas; Francesc Fina; Joan-Antoni Vallès; Rosa Aragonès; Mència Benítez; Edurne Zabaleta
Journal:  BMC Blood Disord       Date:  2008-05-29

10.  Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults.

Authors:  Hiroyuki Kishino; Kenichi Takahashi; Miyuki Sawata; Yoshiyuki Tanaka
Journal:  Hum Vaccin Immunother       Date:  2018-04-12       Impact factor: 3.452

View more
  8 in total

1.  Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes.

Authors:  Ayesa Syenina; Esther S Gan; Justin Z N Toh; Ruklanthi de Alwis; Lowell Z Lin; Christine Y L Tham; Jia Xin Yee; Yan Shan Leong; Huizhen Sam; Charlene Cheong; Yii Ean Teh; Ian L E Wee; Dorothy H L Ng; Kuan Rong Chan; Jean X Y Sim; Shirin Kalimuddin; Eugenia Z Ong; Jenny G Low; Eng Eong Ooi
Journal:  PLoS Biol       Date:  2022-05-31       Impact factor: 9.593

2.  The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.

Authors:  Thomas Hills; Aimee Paterson; Rebecca Woodward; Francis Middleton; Lauren H Carlton; Reuben McGregor; Sebastien Barfoot; Ciara Ramiah; Alana L Whitcombe; Victor M Zimbron; David Mahuika; Joshua Brown; Kate Palmer-Neels; Brittany Manning; Devanshi Jani; Brooke Reeves; Georgia T Whitta; Susan Morpeth; Richard Beasley; Mark Weatherall; Anthony Jordan; Peter McIntyre; Nicole J Moreland; S Ali Mirjalili
Journal:  Vaccine       Date:  2022-06-29       Impact factor: 4.169

3.  Point-of-Care Ultrasound Is a Valuable Modality During Mass COVID-19 Vaccination Campaigns.

Authors:  Wang-Sheng Lin; David Killeen; Chen-Ya Yang
Journal:  J Ultrasound Med       Date:  2021-08-17       Impact factor: 2.754

4.  Localized lipoatrophy and inadvertent subcutaneous administration of a COVID-19 vaccine.

Authors:  Ian F Cook
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

5.  Safety of intramuscular COVID-19 vaccination in patients with haemophilia.

Authors:  Andreas Tiede; Hendrik Leise; Silvia Horneff; Johannes Oldenburg; Susan Halimeh; Christine Heller; Christoph Königs; Katharina Holstein; Christian Pfrepper
Journal:  Haemophilia       Date:  2022-05-13       Impact factor: 4.263

6.  Intramuscular Inoculation of AS02-Adjuvanted Respiratory Syncytial Virus (RSV) F Subunit Vaccine Shows Better Efficiency and Safety Than Subcutaneous Inoculation in BALB/c Mice.

Authors:  Lijun Bian; Yu Zheng; Xiaohong Guo; Dongdong Li; Jingying Zhou; Linyao Jing; Yan Chen; Jingcai Lu; Ke Zhang; Chunlai Jiang; Yong Zhang; Wei Kong
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

7.  Minimizing shoulder injury related to vaccine administration.

Authors:  Ian F Cook
Journal:  Hum Vaccin Immunother       Date:  2021-07-26       Impact factor: 3.452

8.  Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.

Authors:  Nimrod Rahamimov; Veronica Baturov; Adi Shani; Ilai Ben Zoor; Doron Fischer; Anna Chernihovsky
Journal:  Vaccine       Date:  2021-07-02       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.